Novartis Canada is pleased to announce that Fabhalta® (iptacopan capsules) is now available across Canada for adult patients ...

Richard Lafayette, MD, FACP, Stanford University Medical Center, explains the significance of this second approval in a month ...

[NEW YORK] Swiss pharmaceutical giant Novartis said it would invest US$23 billion in the US over the next five years to ensure its key drugs for Americans are made in the country, with the ...

Swiss drugmaker Novartis said today it plans to spend $23 billion to build and expand 10 facilities in the US, as it grapples with renewed threats of drug import duties from the Trump administration.

Swiss pharmaceutical giant Novartis announced Thursday that it plans to expand its manufacturing and research and development activities in the US with an investment of $23 billion over the next ...

During a median follow-up period of 12.3 years, 4399 cases of diabetic microvascular complications were recorded, including 2084 cases of nephropathy, 2401 cases of retinopathy, and 831 cases of ...

Swiss pharma giant Novartis (NOVN: VX) has announced a planned $23 billion investment over five years in US-based infrastructure, ensuring all key Novartis medicines for US patients will be made in ...

Novartis said it plans to invest $23 billion in the construction and expansion of U.S. facilities. The move comes after President Trump earlier this week threatened "major" tariffs on ...

Pharmaceutical company Novartis said it plans to expand U.S.-based manufacturing and research and development, with a total investment of $23 billion over the next five years. The company said it ...

Novartis (NVS) announced a planned $23B investment over five years in U.S.-based infrastructure, ensuring all key Novartis medicines for U.S. patients will be made in the United States. “This ...

Sparsentan is an endothelin and angiotensin II receptor antagonist indicated to slow kidney function decline for adults with primary IgA nephropathy who are at risk for disease progression.